key: cord-1018595-g7ledhuf
authors: Trkulja, Vladimir
title: Fluvoxamine for COVID‐19 ICU patients?
date: 2022-02-07
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.15166
sha: bb58769d3ff822edb66195385c59dac0a57bb7cc
doc_id: 1018595
cord_uid: g7ledhuf

nan

F I G U R E 1 Summary of re-analysis of survival data published in Čaluši c et al. 1 (A) Reconstructed curves of Kaplan-Meier product-limit estimates. Data 1 were read using a digitizing software, and were re-analyzed and curves were drawn using JMP 13 software (SAS Institute Inc., Cary, NC). Ticks at the end of curves indicate censorings. ICU-intensive care unit. In respect to the reported curves (Figure 2 in Čaluši c et al. 1 ), the present one only differ in graduation of the y axis, and the fact that the x axis pointsout day 7, 14, and so on, illustrative of 7-day intervals (days). (B) Estimated probabilities of death during weeks 1 to 5 by treatment (Fluvoxfluvoxamine) and period-specific hazard ratios (HR) with confidence intervals. A complementary log-log model was fitted to reconstituted data using SAS 9.4 for Windows (SAS Inc., Cary, NC)

Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls

Matching methods for causal inference: a review and a look forward

Pharmacokinetics of selective serotonin reuptake inhibitors

Survival Analysis: A Practical Approach

The hazards of hazard ratios

Regression analysis of grouped survival data with application to breast cancer data

Overadjustment bias and unnecessary adjustment in epidemiological studies

Quantifying biases in causal models: classical confounding vs collider-stratification bias

Causal Inference: What If